Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.345
-0.004 (-1.03%)
At close: Apr 28, 2026, 4:00 PM EDT
0.355
+0.010 (2.93%)
Pre-market: Apr 29, 2026, 8:39 AM EDT
Gossamer Bio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 48.47 | 114.7 | - | - | - | |
| Revenue Growth (YoY) | -57.74% | - | - | - | - | |
| Gross Profit | 48.47 | 114.7 | - | - | - | |
| Selling, General & Admin | 37.63 | 36.13 | 38.46 | 47.61 | 45.78 | |
| Research & Development | 174.09 | 138.49 | 135.3 | 170.92 | 170.27 | |
| Operating Expenses | 211.72 | 174.62 | 173.76 | 218.53 | 216.05 | |
| Operating Income | -163.25 | -59.92 | -173.76 | -218.53 | -216.05 | |
| Interest Expense | -10.99 | -11.52 | -13.51 | -13.88 | -19.44 | |
| Interest & Investment Income | 1.97 | 1.78 | 2 | 1.58 | 0.76 | |
| Other Non Operating Income (Expenses) | 3.41 | 0.96 | 6.01 | 0.11 | 1.14 | |
| EBT Excluding Unusual Items | -168.86 | -68.7 | -179.27 | -230.72 | -233.59 | |
| Gain (Loss) on Sale of Investments | 7.28 | 13.06 | 9.45 | 1.41 | -0.34 | |
| Other Unusual Items | -1.4 | - | - | - | - | |
| Pretax Income | -170.46 | -55.64 | -179.82 | -229.38 | -234 | |
| Income Tax Expense | -0.09 | 0.89 | - | - | - | |
| Net Income | -170.37 | -56.53 | -179.82 | -229.38 | -234 | |
| Net Income to Common | -170.37 | -56.53 | -179.82 | -229.38 | -234 | |
| Shares Outstanding (Basic) | 229 | 226 | 153 | 85 | 75 | |
| Shares Outstanding (Diluted) | 229 | 226 | 153 | 85 | 75 | |
| Shares Change (YoY) | 1.01% | 48.23% | 80.46% | 13.00% | 9.24% | |
| EPS (Basic) | -0.75 | -0.25 | -1.18 | -2.71 | -3.13 | |
| EPS (Diluted) | -0.75 | -0.25 | -1.18 | -2.71 | -3.13 | |
| Free Cash Flow | -171.35 | -3.47 | -159.16 | -187.44 | -190.44 | |
| Free Cash Flow Per Share | -0.75 | -0.01 | -1.04 | -2.22 | -2.54 | |
| Gross Margin | 100.00% | 100.00% | - | - | - | |
| Operating Margin | -336.81% | -52.24% | - | - | - | |
| Profit Margin | -351.49% | -49.28% | - | - | - | |
| Free Cash Flow Margin | -353.50% | -3.02% | - | - | - | |
| EBITDA | -163.23 | -59.09 | -172.15 | -216.7 | -214.31 | |
| EBITDA Margin | - | -51.51% | - | - | - | |
| D&A For EBITDA | 0.02 | 0.83 | 1.61 | 1.83 | 1.74 | |
| EBIT | -163.25 | -59.92 | -173.76 | -218.53 | -216.05 | |
| EBIT Margin | - | -52.24% | - | - | - | |
| Revenue as Reported | 48.47 | 114.7 | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.